| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2682caaf0ba44de7b1b320a58df7a3c8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D273-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D273-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate |
2017-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fceaf3c31935577d07aad92a1446ce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f0744e702379672609916d8c69e0f5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a64fceed90a18954bfff358ad2bf46c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba2766d747a1e4aba37d07381979a187
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_804eef1c7b67d98293a89637d2547052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe8e403e8c025cb411862dd9c3f50f11 |
| publicationDate |
2021-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10882830-B2 |
| titleOfInvention |
Crystal form of ozanimod hydrochloride and processes for preparation therefor |
| abstract |
The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023152767-A1 |
| priorityDate |
2016-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |